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Abstract
Neurofeedback (NF) has gained increasing interest in the treatment of attention-deficit/hyperactivity disorder (ADHD). Given 
learning principles underlie NF, lasting clinical treatment effects may be expected. This systematic review and meta-analysis 
addresses the sustainability of neurofeedback and control treatment effects by considering randomized controlled studies 
that conducted follow-up (FU; 2–12 months) assessments among children with ADHD. PubMed and Scopus databases 
were searched through November 2017. Within-group and between-group standardized mean differences (SMD) of parent 
behavior ratings were calculated and analyzed. Ten studies met inclusion criteria (NF: ten studies, N = 256; control: nine 
studies, N = 250). Within-group NF effects on inattention were of medium effect size (ES) (SMD = 0.64) at post-treatment 
and increased to a large ES (SMD = 0.80) at FU. Regarding hyperactivity/impulsivity, NF ES were medium at post-treatment 
(SMD = 0.50) and FU (SMD = 0.61). Non-active control conditions yielded a small significant ES on inattention at post-
treatment (SMD = 0.28) but no significant ES at FU. Active treatments (mainly methylphenidate), had large ES for inattention 
(post: SMD = 1.08; FU: SMD = 1.06) and medium ES for hyperactivity/impulsivity (post: SMD = 0.74; FU: SMD = 0.67). 
Between-group analyses also revealed an advantage of NF over non-active controls [inattention (post: SMD = 0.38; FU: 
SMD = 0.57); hyperactivity–impulsivity (post: SMD = 0.25; FU: SMD = 0.39)], and favored active controls for inattention 
only at pre-post (SMD = − 0.44). Compared to non-active control treatments, NF appears to have more durable treatment 
effects, for at least 6 months following treatment. More studies are needed for a properly powered comparison of follow-up 
effects between NF and active treatments and to further control for non-specific effects.
Keywords Neurofeedback · EEG biofeedback · ADHD · Meta-analysis · Sustainability · Follow-up
Introduction
Clinical guidelines for attention-deficit/hyperactivity disor-
der (ADHD) recommend multimodal treatment approaches, 
with current evidence suggesting that medication, including 
methylphenidate and various amphetamine formulations, in Electronic supplementary material The online version of this 
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conjunction with psychosocial treatment are most effec-
tive in the short-term [1]. Medication treatments have large 
effect size in the acute treatment of ADHD [2] and, when 
combined with psychosocial treatments, large effects up to 
2 years of treatment were observed [3, 4]. Nevertheless, it 
is widely accepted that further treatments with long-lasting 
effects have to be developed and evaluated.
Over the last decade, an increasing number of studies 
investigating non-pharmacological treatments have been 
published. Neurofeedback (NF), which aims at improving 
self-regulation of brain activity (most often the electroen-
cephalogram, EEG) using a brain–computer interface, has 
gained popularity [5]. A promising aspect of neurofeedback 
is that it may rely on procedural learning, thereby poten-
tially allowing lasting effects and thus longer clinical benefit 
after completion of neurofeedback treatment. In their review, 
Arns and Kenemans [6] found that the clinical effects of 
neurofeedback were maintained across 6 and 24-month fol-
low-up periods, with a trend for larger symptom decreases 
for hyperactivity/impulsivity after 24 months than after 
6 months, albeit only based on two randomized studies at 
6 months and only one at the 24-month follow-up, thus limit-
ing the generalizability of the findings. A systematic review 
and meta-analysis that assess the sustainability of clinical 
effects of NF studies is, therefore, desirable.
In recent years, several randomized control studies 
(RCTs) and meta-analyses have been published on the effi-
cacy of neurofeedback for children with ADHD, overall 
with mixed results and interpretations [7–11]. Regarding 
RCTs published over the last decade, one major issue is 
the lack of standardization of neurofeedback protocols and 
implementations. Neurofeedback treatments using theta/
beta, slow cortical potential (SCP), or sensorimotor-rhythm 
(SMR) protocols have been well studied and can be seen as 
‘standard’ neurofeedback treatments (for review and discus-
sion see: Arns et al. [5] and Figure S-2 in Supplementary 
Material). These ‘standard’ protocols have been selected 
as the primary protocols for NF research based on findings 
that children with ADHD have specific deficits in compari-
son with healthy controls: e.g. increased theta/beta ratios 
in subgroups of ADHD patients hypothesized to be related 
to inattention [12]; decreased contingent negative varia-
tion amplitudes (targeted by SCP training) [13]; addressing 
hyperkinetic behavior by means of training sensorimotor 
rhythm [14]. Application of these standard neurofeedback 
protocols in ADHD have most consistently resulted in clini-
cal benefit in children with ADHD, whereas application of 
other neurofeedback protocols has yielded more variable and 
mixed results [5, 8]. A second issue with currently available 
neurofeedback RCTs is that several studies deviated from 
their initial clinical trials register, with samples ranging from 
34% [15] to 60% [16, 17] smaller than their preregistered 
sample size. This raises the likelihood of over-interpreting 
results from these studies, which are insufficiently powered. 
This issue is addressed using meta-analyses since effects are 
combined across studies, resulting in increased statistical 
power.
A third issue concerns the specificity of NF treatment 
effects. While NF has been shown to be beneficial for the 
treatment of ADHD symptoms, it remains a debate whether 
behavioral improvements are the result of specific aspects 
of the NF treatment such as the style of training, or active 
learning of control over their brain state that is then gen-
eralized to daily life or whether non-specific treatment 
effects such as unconditional positive regard of the thera-
pist, positive expectation of change, or repeated practice of 
sitting at a computer for increasing lengths of time leads 
to behavioral change. To control these non-specific or pla-
cebo effects, double-blind placebo-controlled studies are 
often requested—comparable to what is considered as gold 
standard in drug research. However, in regard to NF, there 
are methodical and ethical issues to consider which have led 
to the development of control conditions such as cognitive 
training or EMG biofeedback and assessments for placebo 
factors via evaluation scales [18, 19]. Though it is known 
that placebo effects may last over longer periods [20], it 
seems unlikely that they grow larger over time. Hence focus-
ing on longer-term outcomes of NF may also help to clarify 
the placebo/specific vs. non-specific issue.
Two recent meta-analyses on the acute efficacy of neu-
rofeedback for children with ADHD published by the Euro-
pean ADHD Guidelines Group (EAGG) have used the inter-
esting concept of most-proximal (e.g. least blinded, often 
parent ratings) versus probably blinded measures (most often 
teacher ratings), assuming that the probably blinded meas-
ures (i.e., teacher ratings) are less susceptible to expecta-
tion/non-specific effects and, therefore, more valid [8, 11]. 
However, this approach has limitations. For example, par-
ent–teacher correlations on behavior rating scales are only 
modestly correlated (ranging from 0.23 to 0.49) [21, 22], 
suggesting different aspects of the disorder may be detected 
by different raters or in different settings. Furthermore, in a 
large candidate gene study, parent-rated hyperactive–impul-
sive behaviors were significantly associated with candidate 
gene pathways whereas teacher ratings were not [23]. Addi-
tionally, teacher-ratings are sensitive to effects of methylphe-
nidate [24], which could possibly skew the interpretation of 
studies that randomize ADHD treatments against a methyl-
phenidate control, when primarily relying on teacher reports. 
Finally, for investigating long-term effects, it may not be 
advisable to rely on teacher ratings, since the child may have 
more than one teacher over time, potentially compromising 
the reliability of the rating.
A second limitation of the aforementioned meta-analyses 
is the use of between-group effect sizes, which is a good 
practice for compiling results from studies that used similar 
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designs and control groups; comparing for example, psycho-
stimulants to placebo. However, the utility of this method for 
studying results across neurofeedback studies, with various 
kinds of control groups (ranging from waiting lists, cogni-
tive training to medication), is more challenging. Therefore, 
while between-group effect sizes are useful for controlling 
for non-specific effects of treatment, they can miss clinical 
effects of neurofeedback that are masked by the active or 
semi-active control conditions, thus warranting the use of a 
within-group effect-size approach, for example as used by 
Arns et al. [7], or separately analyze the results for active vs. 
semi-active control groups.
To address the above concerns, we have conducted a 
systematic review and meta-analysis of the post-treatment 
follow-up period of randomized EEG NF studies among 
children and adolescents with ADHD. Methodologically, 
we (1) used within-group effect sizes to address the issue 
of different control groups; (2) used between-group effect 
sizes to control for non-specific effects of treatment; (3) 
applied a meta-analytical approach to address the issue of 
underpowered studies; and (4) focused on the sustainability 
of treatment effects by looking specifically at the follow-up 
(FU) period (i.e., pre-FU, post-FU time points), which will 
provide information regarding the plausibility of sustainable 
NF effects, relative to other treatments, in ADHD.
Method
Study selection
The protocol of this meta-analysis was not preregistered. 
A literature search was conducted up to 29th of Novem-
ber 2017 via PubMed and Scopus by author JVD, look-
ing for studies investigating Neurofeedback or EEG Bio-
feedback in ADHD using combinations of the following 
keywords: ‘Neurofeedback’, ‘EEG Biofeedback’, ‘Neu-
rotherapy’, ‘SCP’ OR ‘Slow Cortical Potentials’ AND 
‘ADHD’, ‘ADD’, ‘Attention Deficit’ OR ‘Attention Deficit 
Hyperactivity Disorder’. Furthermore, prior meta-analyses 
and systematic review reference lists were inspected for 
potentially missed studies [7, 8, 10, 11]. After exclusion of 
duplicate publications, abstracts were screened for inclu-
sion criteria first by author HH and then by a research 
assistant to prevent missing studies. Studies that remained 
of interest were then screened based on their full text by 
JVD. Inclusion criteria were: (1) randomized controlled 
EEG neurofeedback trials published in peer-reviewed 
journals; (2) primary diagnosis of ADHD; (3) mean child 
age < 18 years old; (4) available data at a follow-up (FU) 
time point for 2 to 12 months post-treatment; (5) stand-
ardized mean and standard deviations (SD) for all three 
assessments (pre, post, and FU) for at least one of the 
following domains had to be available: inattention, hyper-
activity, or hyperactivity/impulsivity ratings from a DSM-
IV/5-based rating scale (these values were taken based on 
availability with parental ratings taking priority, then self-
ratings and lastly teacher ratings); (6) publication avail-
able in English; (7) total study sample larger than N = 10; 
8) less than 50% of participants began or stopped taking 
medication between post and FU assessments.
In most of the studies, ‘standard’ neurofeedback protocols 
[5] were used, i.e., theta/beta and theta/SMR (sensorimotor 
rhythm) training (defined as a down-training of theta and 
up-training of beta and SMR, respectively) and slow corti-
cal potential training (SCP) training (addressing modulation 
of positive and negative SCPs), for details see Table 1 and 
Supplementary Figure S-2. Exceptions were the studies of 
Arnold et al. [25] and Bink et al. [26] which targeted more 
EEG frequency bands (theta, alpha, SMR, and beta), and a 
sensitivity analysis was conducted to separately assess the 
effects for standard protocols. When the means and SDs 
from a given study were not available, or it was unclear if 
planned follow-up measurements were published, this infor-
mation was requested via email from the authors. If authors 
did not respond or did not provide the missing information, 
and if there was not sufficient information available based 
on the publication, the study was excluded from the meta-
analysis. Studies were additionally screened for duplicate 
data based on author, publication year, participant numbers 
and trial registration number (if available). When possible 
duplicate data was found, the authors were contacted to 
clarify whether the data sets were independent.
Data extraction/outcome measures
Data were first extracted by JVD and checked by HH. The 
following pre-, post- and FU-assessment measures were 
extracted from the included studies:
1. Demographic and clinical data: age (mean and standard 
deviation), medication use, ADHD subtype.
2. Experimental procedure: NF method, control method, 
feedback electrode, average number of sessions, session 
length.
3. Outcome measures:
  Symptom domains: Assessed from parent report with 
a validated ADHD rating scale (e.g., DSM-IV rating 
scale [27], Conners [28], Barkley [29], FBB-HKS [30], 
SWAN [31])
 (i) Inattention
 (ii) Hyperactivity/impulsivity (if no combined 
measure was available, the hyperactivity score 
was used).
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These measures were used as treatment endpoints at post-
treatment and FU relative to baseline values. Additionally, 
the change from post-treatment to FU was assessed to deter-
mine if changes occurred after the treatment had stopped.
Meta‑analysis
A random effects model (due to inherent heterogeneity 
between studies) and the inverse variance statistical method 
was used to calculate the standardized mean difference 
(SMD), 95% confidence intervals, and χ2 statistic using 
RevMan version 5.3 [32]. Within-group and between-group 
analyses were conducted for the following time points using 
the means and standard deviations provided in the papers or 
by the authors: (1) pre- and post-treatment; (2) pre-treatment 
and follow-up; (3) post-treatment and follow-up. Within-
group analyses used the values as presented in the papers (no 
additional calculation was necessary). Between-group means 
were calculated by subtracting the mean of the second time 
point from the mean of the first time point (ex. pre-treatment 
minus post-treatment, pre-treatment minus FU-treatment, 
post-treatment minus FU-treatment). The standard devia-
tion of the first point was used for analysis.
Although active treatment effects are not the main focus 
of this paper, the control conditions were analyzed as a 
whole and assessed using two sub-analyses (non-active and 
active control conditions) to provide a frame of reference 
for the effects of neurofeedback against different type of 
controls. Due to the diversity of the control conditions, we 
chose to separate them as ‘active’ (proven to have a clinical 
effect in the treatment of ADHD: methylphenidate and self-
management training) and ‘non-active’ (all conditions that 
do not classify as active). For a more detailed explanation 
of these groupings see Table S-2 in the supplement. See 
Tables S-5 and S-6 for values used. When the χ2 statistic of 
a sample (Qt) was significant (p < 0.05)—indicating that 
the variance among effect sizes is greater than expected by 
sampling error—studies were assessed for possible heteroge-
neity causes and the resulting studies were omitted from the 
meta-analysis, for example based on the type of treatment 
(separating active and non-active conditions in the control 
groups). Active treatments were defined as medication or 
psychotherapy (self-management) that was started system-
atically after pre-treatment assessment. Additionally, a sen-
sitivity analysis was conducted including only studies that 
used standard NF protocols (theta/beta, theta/SMR, or SCP). 
To assess publication bias, MetaWin version 2.1 [33] was 
used to calculate the fail-safe number (Rosenthal’s method: 
a < 0.05).
Results
A total of ten studies met inclusion criteria for at least one 
of the parameters and conditions, resulting in ten studies in 
the NF arm and nine studies in the control arm (two control 
studies had two control groups [34, 35]). See Figure S-1 
for the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) inclusion flow diagram and 
Table 1 for characteristics of included studies. The PRISMA 
checklist is available in the supplementary material (Table 
S-1). The supplementary material has a complete list of 
inclusions (Table S-4) and exclusions (Table S-3). Included 
studies resulted in a total of 506 participants with ADHD 
(256 neurofeedback, 250 control). Follow-up time periods 
were 2 months (K = 2), 3 months (K = 1), 6 months (K = 6) 
and 12 months (K = 1).
The control group from Heinrich et al. [36] was excluded 
because most of the controls began psychotherapy between 
post and FU (personal communication with first author). The 
2-month FU time point from the Meisel et al. [37] study 
was included instead of the 6-month FU because over 50% 
of their NF participants began medication between post- 
and 6-month FU measurements while only two participants 
started taking medication between post and 2-month FU. The 
combined NF + MPH arm of Duric et al. [38] was excluded 
since the NF treatment was accompanied by another active 
treatment, which did not allow differentiation of treatment 
effects; this differed from other studies in which NF children 
could receive medication if they had been already medicated 
prior to study participation, ensuring that the baseline meas-
urements already included medication effects. The supple-
mentary analysis was used from Gelade et al. [35] instead 
of the primary analysis to account for participant drop-out 
and medications change. For the majority of the studies, data 
were available for participants who completed assessments 
at all three time points (pre-, post-, FU) with the exception 
of Li et al. [39], in which drop-out from baseline to FU were 
3.13% (N = 1) for the NF group and 9.38% (N = 3) for the 
control group.
Regarding medication change for included studies, the 
number of participants who began or stopped taking med-
ication did not change over time for most of the studies, 
with the exception of four [25, 26, 37, 40]. In summary: of 
the total NF participants three stopped taking medication 
[pre-post (N = 2), post-FU (N = 1)], while nine began tak-
ing medication [pre-post (N = 1), post-FU (N = 8)]; for the 
control group only one participant stopped taking medica-
tion from post to FU time point. Dosage was allowed to 
be changed in five studies (see Table 1); however, dosage 
change was variable with some groups maintaining (one NF, 
one control), decreasing (two NF) or increasing (two NF, 
three control) dosage. See Table S-4 for details.
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Within‑group analyses
Inattention
Forest plots and results for inattention are presented in 
Fig. 1; Bar plots in Figure S-3. The test for heterogeneity 
was not significant for NF at pre-post (χ2 = 9.69, df = 9, 
n.s.) or pre-FU (χ2 = 12.37, df = 9, n.s.), while controls 
did display significant heterogeneity for both pre-post 
(χ2 = 27.95, df = 10, p < 0.05) and pre-FU (χ2 = 29.60, 
df = 10, p < 0.05) when all controls were included. When 
considering non-active controls only, heterogeneity was no 
longer significant for the pre-post measurement (χ2 = 6.72, 
df = 6, n.s.), but remained significant for the pre-FU meas-
urement (χ2 = 14.02, df = 6, p < 0.05). When only active 
controls were included, pre-post heterogeneity remained 
significant (χ2 = 10.12, df = 3, p < 0.05) while pre-FU 
(χ2 = 0.48, df = 3, n.s.) was not significant. These results 
suggest that when heterogeneity is significant for controls, 
it will be useful to examine SMDs for active and non-active 
controls separately, which will be done for the remainder 
of the paper. This reduces the number of studies examined, 
however, and caution will be used when interpreting the 
results. Heterogeneity was non-significant for all groups for 
the post-FU measurement: NF (χ2 = 2.29, df = 9, n.s.); non-
active (χ2 = 4.05, df = 6, n.s.); active (χ2 = 7.40, df = 3, n.s.).
NF yielded a significant medium effect size (SMD = 0.64; 
95% CI 0.45, 0.82) for the change from the pre- to post-
treatment measurements and a significant large effect size 
(SMD = 0.80; 95% CI 0.58, 1.01) for the change from pre- 
to FU measurement; however, post-treatment to FU was 
not significant (SMD = 0.14; 95% CI − 0.03, 0.31). For 
non-active controls, a small, significant effect for pre-post 
(SMD = 0.28; 95% CI 0.05, 0.51) was found but the small 
effect at pre-FU was no longer significant (SMD = 0.29; 
95% CI − 0.04, 0.63). When looking at only active controls, 
there were large, significant effect sizes at both pre-post (sig-
nificant heterogeneity) (SMD = 1.08; 95% CI 0.45, 1.72) 
and pre-FU (non-significant heterogeneity) (SMD = 1.06; 
95% CI 0.73, 1.39). Post-treatment to FU was not significant 
for either control group. The fail-safe numbers for NF were: 
pre-post (156.0), pre-FU (190.7). For the control conditions, 
the fail-safe numbers were: 1. non-active controls: pre-post 
(11.2), pre-FU (1.1); 2. active controls: pre-post (13.5), pre-
FU (55.2).
Hyperactivity/impulsivity
Forest plots and results for hyperactivity/impulsivity are 
presented in Fig. 2; Bar plots in Figure S-3. The test for 
heterogeneity was not significant for any of the hyperactiv-
ity/impulsivity measurements, indicating that the variance 
of SMD was not large enough to be attributed to sampling 
error only (see Fig. 2). For comparability to the inatten-
tion domain, the active and non-active control groups are 
reported separately.
For NF, a significant medium effect size (SMD = 0.50; 
95% CI 0.33, 0.68) was found for the pre-post measurement 
and a medium effect size (SMD = 0.61; 95% CI 0.43, 0.79) 
for the pre-FU measurement; the post-FU measurement was 
not significant (SMD = 0.11; 95% CI − 0.06, 0.28).
Analysis of non-active control groups indicated that none 
of the measurements (pre-post, pre-FU, post-FU) were sig-
nificant. When only active controls were considered, there 
were significant medium effect sizes for both pre-post 
(SMD = 0.74; 95% CI 0.41, 1.06) and pre-FU (SMD = 0.67; 
95% CI 0.35, 0.99). For both control analyses, post-FU was 
not significant. The fail-safe numbers for NF were: pre-post 
(107.6), pre-FU (163.4). For the controls, the fail-safe num-
bers were: 1. non-active controls: pre-post (0), pre-FU (0); 
2. active controls: pre-post (25), pre-FU (18.4).
Between‑group meta‑analysis
Forest plots and results for inattention and hyperactivity/
impulsivity are presented in Fig. 3.
Inattention
The test for heterogeneity was significant when including all 
studies at pre-post (χ2 = 30.60, df = 10, p < 0.05) and signif-
icant at pre-FU (χ2 = 33.27, df = 10, p < 0.001). Considering 
only trials with non-active control conditions, heterogeneity 
was not significant for the pre-post measurement (χ2 = 7.83, 
df = 6, n.s.) or the pre-FU measurement (χ2 = 7.48, df = 6, 
n.s.). For active controls, heterogeneity was not significant 
for pre-post (χ2 = 5.00, df = 3, n.s.) or for pre-FU (χ2 = 7.05, 
df = 3, n.s.).
When including only studies with non-active con-
trol conditions, a significant small effect size for pre-post 
(SMD = 0.38; 95% CI 0.14, 0.61) and a medium effect size 
for pre-FU (SMD = 0.57; 95% CI 0.34, 0.81) were observed 
favoring neurofeedback. When only active controls were 
included, a pre-post effect size favoring active controls was 
significant (SMD = − 0.44; 95% CI − 0.86, − 0.02) but at 
pre-FU it was no longer significant. Post-training to FU was 
not significant for either analysis.
Hyperactivity/impulsivity
The test for heterogeneity was not significant for any of the 
hyperactivity/impulsivity measurements, indicating that 
the variance of SMD was not large enough to be attributed 
to sampling error only. The between-group analysis of all 
control groups resulted in a significant small effect size 
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favoring NF (SMD = 0.32; 95% CI 0.15, 0.49) at pre-FU, 
pre-post was not significant. When including only non-
active control groups (done for comparison with inatten-
tion, not due to heterogeneity), results favored NF with a 
significant small effect for the pre-post (SMD = 0.25; 95% 
CI 0.05, 0.45) measurement and a small effect for pre-FU 
(SMD = 0.39; 95% CI 0.19, 0.59). Including only active 
controls resulted in no significant findings for either pre-
post or pre-FU. For both control analyses post-FU was not 
significant; however, post-FU did show a trend toward sig-
nificance favoring neurofeedback over all control groups 
(p = 0.08; SMD = 0.15; 95% CI − 0.02, 0.32].
Sensitivity meta‑analysis: ‘standard’ NF training
See Tables S-7 and S-8 for details regarding this analysis.
Inattention
The tests for heterogeneity as well as effect sizes were simi-
lar to those seen in the within-group and between-group 
analyses including all studies, with slightly stronger effect 
sizes seen for the sensitivity analysis regarding pre-post and 
pre-FU time points (increase in SMD ranging from 0.01 to 
0.14), however, with small changes in both directions for 
post-FU (change ranging from − 0.02 decrease to 0.02 
increase).
Hyperactivity/impulsivity
The tests for heterogeneity as well as effect sizes were simi-
lar to those seen in the within-group and between-group 
analyses including all participants (decrease of 0.01 SMD 
to increases in SMD up to 0.02).
Discussion
This meta-analysis investigated the effects of neurofeedback 
and control conditions directly after treatment and during a 
follow-up period (2–12 months post-treatment), in which 
Fig. 1  Forest Plot of within-group analysis for inattention param-
eter. Total standardized mean difference (SMD) with 95% confidence 
interval, overall effect, and heterogeneity are reported. Due to signifi-
cant heterogeneity in the initial control analysis, additional analyses 
examining non-active and active controls separately were included. 
Pre-Post refers to the difference in means at pre- and post-measure-
ment, and similarly for pre-FU and post-FU
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no additional neurofeedback sessions or booster sessions 
were performed. For neurofeedback, a medium SMD for 
inattention and hyperactivity/impulsivity were found post-
treatment, which changed to a large SMD for inattention and 
remained a medium SMD for hyperactivity/impulsivity at 
follow-up (relative to baseline). Non-active control groups 
yielded a significant small effect size at pre-post that was 
no longer significant at FU for inattention, and there were 
no significant effects found for the hyperactivity/impulsivity 
domain. Active controls had significant large effect sizes for 
inattention and medium effect sizes for hyperactivity at both 
pre-post and pre-FU. The between-group analysis was found 
to significantly favor NF over non-active control groups for 
both inattention and hyperactivity/impulsivity at pre-post 
(small effect sizes) and pre-FU (small to medium effect 
sizes). Active controls were found to be significantly supe-
rior regarding inattention at pre-post but no longer at follow-
up. In summary, focusing on the pre-treatment to follow-up 
results, neurofeedback was superior to non-active control 
groups and similarly effective for inattention and hyper-
activity/impulsivity compared to active treatments. These 
findings provide evidence that there are sustained clinical 
benefits after neurofeedback and active treatments over an 
average 6–12 month follow-up period, whereas effects of 
non-active control groups are no longer significant at FU.
The significant improvement in symptoms at FU for both 
inattention and hyperactivity–impulsivity in the neurofeed-
back conditions indicates that NF results in lasting effects for 
approximately 6 months and potentially up to 1 year. Com-
parison of effect-sizes between neurofeedback and active 
control groups showed overlapping confidence intervals 
(also visualized in Figure S-3), and no significant difference 
in the between-group analysis, suggesting NF and active 
controls having similar effects in the respective FU period; 
however, this finding needs to be viewed with caution due 
to the small number of studies in the active controls groups 
(K = 4). The tendency in the within-group analyses for a 
small further improvement in the NF group (inattention: 
Fig. 2  Forest Plot of within-group analysis for hyperactivity/
impulsivity parameter. Total standardized mean difference (SMD) 
with 95% confidence interval, overall effect, and heterogeneity are 
reported. Analysis of the control condition separately for non-active 
and active controls was conducted for comparability to the inattention 
parameter analysis. Pre-Post refers to the difference in means at pre- 
and post-measurement, and similarly for pre-FU and post-FU
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SMD = 0.14; hyperactivity/impulsivity: SMD = 0.11) from 
post-treatment to FU, albeit not significant, is in line with the 
further improvement effects seen after two-year follow-up 
[6, 41]. This tendency was non-existent and moves primarily 
in the opposite direction (SMD = − 0.1 to 0) for the active 
and non-active controls (see Figure S-3). Accordingly, post-
FU results of the between-group analyses were slightly in 
favor of NF (SMDs between 0.1 and 0.2, with a statistical 
trend for hyperactivity/impulsivity) suggesting that effects 
may become significant with further studies available. In any 
case, current results do support the sustainability of the clin-
ical benefits of neurofeedback after cessation of treatment.
Regarding the use of medication, we only focused on 
follow-up periods of 2–12 months, and effects for active 
treatments demonstrated sustained clinical benefit for these 
periods (in which children were actively taking medication). 
This is line with previous studies which demonstrated clini-
cal benefits of psychostimulant medication at 12 months [42] 
and 24 months [3, 4]; however, the clinical benefits of psy-
chostimulant medication (when naturalistically assessed) are 
not empirically supported for longer follow-up periods of 
2–8 years [43–45]. Despite this, recent epidemiological stud-
ies have found that continued controlled medication intake 
can have positive benefits for patients with ADHD [46–48]. 
However, Swanson et al. [49] reported that at 12–16-year 
follow-up of long-term medication use (both consistent and 
inconsistent use over this time period) was not associated 
with reduced symptom severity, but it was associated with 
decreased adult height. These contrasting findings suggest 
that while medication may have some long-term benefits, 
the adherence of medication intake may be problematic and 
long-term medication exposure may be related to potential 
Fig. 3  Forest Plot of between-group analysis for inattention and 
hyperactivity/impulsivity parameter. Total standardized mean differ-
ence (SMD) with 95% confidence interval, overall effect, and hetero-
geneity are reported. Analysis of the studies separately for non-active 
and active controls was conducted for comparability to the inattention 
parameter analysis. Pre-Post refers to the difference in means at pre- 
and post-measurement, and similarly for pre-FU and post-FU
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physical side effects. The follow-up periods used in our 
study were probably not long enough to demonstrate the 
decreased efficacy of medication as reported in the above 
studies [43–45], and since these studies were controlled dur-
ing the FU periods and not naturalistic, it is likely that medi-
cation adherence was high. While NF follow-up treatment 
effects have not been studied for such long-time intervals, 
the short-term clinical effects of NF appear to be sustained 
(without continued training) for an average 2–12 month FU, 
suggesting potential promise of this approach for sustained 
clinical benefit in ADHD.
Interestingly, a strong point of our findings is that, despite 
past heterogeneity in the application of neurofeedback pro-
tocols [5], most of the studies included in this paper used 
‘standard NF protocols’, the exceptions being Arnold et al. 
[25] and Bink et al. [26]. Additionally, Arnold et al. [25] 
used an ‘entertaining’ NF protocol that may not be compat-
ible with principles of learning theory. However, the use of 
uniform protocols by most of the papers is also evidenced by 
the absence of significant heterogeneity. Considering only 
standard protocols, we found that the results supporting NF 
over non-active controls are slightly strengthened when only 
including standard NF protocols. This finding supports the 
continued use of these protocols for future NF studies. Addi-
tionally, our significant findings are in line with those of 
Cortese et al. [8] who demonstrated significant between-
group effects even for ‘probably blinded’ ratings (teacher 
ratings) at post-treatment when only standard NF protocols 
for total ADHD and inattention symptoms were considered.
When considering placebo effects of NF training, they 
may still operate at follow-up but we are not aware of ten-
dencies for further improvements of placebo effects for 
other treatments of other disorders. NF treatment is found 
to be superior to non-active controls in this analysis, and 
the effects of non-active controls were not significant at FU, 
neither for inattention nor hyperactivity/impulsivity. These 
findings support the idea that NF does indeed have a differ-
ent, specific effect due to its actual training and not simply 
due to the non-specific or placebo effects related to the set-
ting, the therapist–patient relationship or expectations. To 
verify this more RCT’s using controls that closely mimic 
NF training are required.
Possible limitations and open questions
Results of the current meta-analysis should be interpreted in 
line with its limitations.
While some of the studies included here do simultane-
ously use medication and NF (which may influence the 
results), the number of participants taking medication did 
not change for most studies, (only in two studies the NF 
participants began taking medication between pre- and FU 
measurement [25, 37]), suggesting that medication changes 
are not an explanation for the effects found here. Addition-
ally, while dosage was allowed to be changed in five of these 
studies, two NF groups decreased dosage and two increased 
dosage while three control groups increased dosage. These 
changes should not bias the data in favor of the NF, but 
rather suggest that the NF effects may be slightly masked by 
the dosage increase seen in the control groups.
When comparing the between-group effect sizes for pre- 
to post-treatment between this study (Fig. 3) and the latest 
EAGG meta-analysis by Cortese et al. [8], a small effect 
for inattention (SMD = 0.36) and hyperactivity/impulsivity 
(SMD = 0.26) was found. In the current study, SMD’s are 
lower when including all controls (inattention: SMD = 0.09; 
hyperactivity/impulsivity: SMD = 0.16) and nearly identi-
cal when considering only non-active controls (inattention: 
SMD = 0.38; hyperactivity/impulsivity SMD = 0.25). This 
indicates that the studies we have included are representa-
tive and not biased towards more effective studies (opposite 
file-drawer problem, i.e. higher likelihood that positive stud-
ies are more often published). But, while we attempted to 
address the file drawer problem by assessing the fail-safe 
numbers for our analysis, a potential reporting bias cannot be 
definitively excluded. However, our finding of much larger 
fail-safe numbers for NF (generally ≥ 100) than for control 
conditions (active < 56, non-active < 12) do suggest that 
the NF condition results are probably not influenced by a 
reporting bias.
Inherently when investigating FU periods, there are addi-
tional limitations involved including completer bias (a bias 
is introduced because of the factors that cause a person to be 
involved during a FU time-point) and the lack of an intention 
to treat analysis (ITT) available for studies using a FU time 
point. This type of analysis is considered more conservative 
than the per protocol analyses found in the majority of the 
papers included here. We chose specifically to not run a risk 
of bias assessment because this model does not work well for 
NF studies since it relies heavily on blinding, which poses a 
problem since most NF studies were not blinded.
As already mentioned, more carefully designed RCTs 
with longer follow-up time periods are needed before defi-
nite conclusions can be drawn. However, the meta-analysis 
of Cortese et al. [8] on the acute effects of NF was comprised 
of studies with a comparable design (“well-controlled”) and 
about the same number of participants (ca. 500). Therefore, 
this meta-analysis on follow-up effects at the present time 
may also allow us to derive the first relevant conclusions 
about the lasting effects of NF treatment.
Future research should focus on addressing both post- and 
FU-effects of NF and other non-pharmacological treatments 
for ADHD. Additionally, based on the current findings of 
within-group effects, placebo or non-specific treatment 
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effects in NF cannot be ruled out and better controls for these 
effects should continue to be investigated. Finally, it should 
be noted that the specificity of neurofeedback effects cannot 
only be derived from RCTs and a meta-analysis of RCTs 
investigating behavioral outcome. Associations between the 
behavioral and neurophysiological level (e.g., neuroregula-
tion skills) have already been documented with respect to the 
post-treatment outcome [17, 50, 51], but are largely missing 
from the literature that has conducted FU measurements. 
These parameters provide an additional method to evaluate 
treatment effects and should be included in future research 
of long-term follow-ups.
Conclusion
Our meta-analytic results of NF treatment follow-up sug-
gest that there are sustained symptom reductions over time 
in comparison with non-active control conditions. The 
improvements seen here are comparable to active treat-
ments (including methylphenidate) at a short-term FU of 
2–12 months. As such, NF can be considered a non-phar-
macological treatment option for ADHD with evidence of 
treatment effects that are sustained when treatment is com-
pleted and withdrawn. Future research should focus on the 
comparison of standardized NF treatments with standard-
ized control treatments, controlling for unspecific effects 
and changes in additional treatments (medication). Given 
the need for additional treatments for ADHD with long-term 
outcomes, clinical trials of NF should aim for primary out-
come measures that compare pre-treatment with systematic 
long-term follow-up behavioral ratings, to address sustain-
ability of effects.
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